- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 436 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2022
- U.S. locations
- 6
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
- Interventions
- Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- oxaliplatin, irinotecan, leucovorin, 5-fluorouracil, capecitabine, radiation, surgery, gemcitabine
- Drug · Radiation · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 14
- States / cities
- La Jolla, California • Chicago, Illinois • Evanston, Illinois + 11 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- LDE225-600mg, Gemcitabine, nab-paclitaxel, LDE225-400mg, LDE225-800mg
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Interventions
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy, Surgery
- Biological · Radiation · Procedure
- Lead sponsor
- Candel Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 2
- States / cities
- Fort Myers, Florida • Columbus, Ohio
- Conditions
- Adenocarcinoma of Pancreas
- Interventions
- Irinotecan, Oxaliplatin, Leucovorin, 5-FU
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy
- Other · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, Leucovorin, NIS793, Chemoradiation, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Kimberly Perez, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreas Adenocarcinoma
- Interventions
- Nab-paclitaxel + Gemcitabine, modified FOLFIRINOX (mFOLFIRINOX)
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- PTM-101
- Drug
- Lead sponsor
- PanTher Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Detroit, Michigan • Lake Success, New York + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- TTI-101, Stereotactic body radiation therapy
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • St Louis, Missouri
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
- Other · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, Oxaliplatin, Erlotinib
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- Proton Radiation, Capecitabine, Surgical resection
- Radiation · Drug · Procedure
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2040
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Warrenville, Illinois • Flint, Michigan + 1 more
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- 3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
- Drug · Procedure · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pancreas Adenocarcinoma
- Interventions
- Cyberknife
- Radiation
- Lead sponsor
- Capital Health System, Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Pennington, New Jersey
- Conditions
- Pancreatic Adenocarcinoma, Borderline Resectable Adenocarcinoma of the Head of the Pancrease
- Interventions
- radiation therapy, surgery, mFOLFIRINOX, FOLFOX
- Radiation · Procedure · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2016
- U.S. locations
- 154
- States / cities
- Mobile, Alabama • Antioch, California • Berkeley, California + 122 more
- Conditions
- Pancreatic Cancer
- Interventions
- Stereotactic Body Radiation Therapy, Preoperative Fractionated Radiation Therapy and Chemotherapy
- Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2031
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
- Drug
- Lead sponsor
- Benaroya Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride, Leucovorin, Leucovorin Calcium, Nivolumab, Oxaliplatin, Therapeutic Conventional Surgery
- Drug · Biological · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Neoplasms
- Interventions
- Stereotactic Body Radiation
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Interventions
- Nab paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more